carocell bio

menu.png

Carocell Bio’s research products are designed to interrupt the inflammatory cascade at a critical juncture through a unique combination of therapeutic peptides and its nano-polymer delivery technology

Our research and what we do

Carocell Bio – developing new possibilities for the treatment of inflammatory diseases. 

Carocell Bio has licensed two very important components that have the potential to develop into innovative new treatments for patients with serious inflammatory diseases, including inflammatory bowel disease (IBD), atopic dermatitis and burns.

  • Novel therapeutic peptides: JEL3108, JEL0305, JEL1103, JEL2603 and JEL0802
  • Safe, established nano-polymer delivery technology

Carocell Bio’s peptides

Carocell Bio’s therapeutic peptides are highly potent and selective inhibitors of intracellular p38 mitogen-activated protein (MAP) kinases.

p38 MAP kinases play a vital role in inflammation and other biological processes. IBD, rheumatoid arthritis, tumorigenesis and Alzheimer’s disease are all regulated in part by the p38 pathway. Its activation increases the production of key pro-inflammatory cytokines (interleukin (IL)-1b, TNF-a and IL-6) and other inflammatory-related molecules. As a therapeutic target, it is well-known that inhibiting the p38 pathway reduces proinflammatory cytokine secretion and eases inflammation.

Carocell Bio’s peptides are highly selective and exquisitely specific blockers of p38a. This specificity means that tiny doses are expected be required to achieve therapeutic efficacy. They will be delivered topically in combination with their licensed nano-polymer delivery technology to enable intracellular delivery. The peptides are rapidly broken down into simple and naturally occurring amino acids.

Carocell Bio’s delivery technology

Carocell Bio’s therapeutic peptides are highly potent and selective inhibitors of intracellular p38 mitogen-activated protein (MAP) kinases.

p38 MAP kinases play a vital role in inflammation and other biological processes. IBD, rheumatoid arthritis, tumorigenesis and Alzheimer’s disease are all regulated in part by the p38 pathway. Its activation increases the production of key pro-inflammatory cytokines (interleukin (IL)-1b, TNF-a and IL-6) and other inflammatory-related molecules. As a therapeutic target, it is well-known that inhibiting the p38 pathway reduces proinflammatory cytokine secretion and eases inflammation.

Carocell Bio’s peptides are highly selective and exquisitely specific blockers of p38a. This specificity means that tiny doses are expected be required to achieve therapeutic efficacy. They will be delivered topically in combination with their licensed nano-polymer delivery technology to enable intracellular delivery. The peptides are rapidly broken down into simple and naturally occurring amino acids.

.

Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005, 15, 11–18

Docena G et al. Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease. Clin Exp Immunol 2010, 162, 108-15

FIND OUT HOW YOU CAN INVEST IN OUR TECHNOLOGY

invest in our income generating business

106 billion dollar market

talk-to-us-icon.png

Talk to us

If you would like to speak to us in detail about investing, tax benefits, donating or assisting us in any way at all, please contact us via the details below and we will get back to you as soon as possible.

bridge biotec facebookbridge biotec twitterbridge biotec linkedinbridge-youtube-60x60.png

Contact

Email: contact@carocellbio.com
UK: +44 (0) 20 3097 1979
US: +1 212 863 9902

USA Office

Carocell Bio, Inc.
500 Delaware Avenue
Ste#1, 1960
Wilmington
DE 19899
U.S.A.

UK Office

©2018 Carocell Bio Ltd.

The BioHub at Alderley Park
Mereside, Alderley Park
Macclesfield
SK10 4TG